Post-earnings recap
Reported
Wed, Jul 19, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. The market reacted positively despite the lack of revenue data and specific guidance. Investors may be encouraged by the management's focus on upcoming clinical trial results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | +29.04% |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about their clinical pipeline. They emphasized the significance of future data releases while refraining from offering specific guidance.
Management expressed confidence in ongoing clinical trials.
They highlighted the importance of upcoming data releases.
No specific guidance was provided for future earnings.